Transcatheter aortic valve replacement (TAVR) annual report 2023_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

 PAN Wenzhi ¹ , FANG Yanxing ¹ , LI Jie ² , LI Fei ³ , ZHOU Daxin ¹ , GE Junbo ¹

1. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, 200032, P. R. China;
2. Department of Cardiology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, P. R. China;
3. Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi’an, 710032, P. R. China;

Corresponding author：

PAN Wenzhi, Email: peden@sina.com

Keywords：

Transcatheter aortic valve replacement; progress; annual report

DOI：

10.7507/1007-4848.202401070

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Transcatheter aortic valve replacement (TAVR) has seen a surge in clinical research, basic research, and innovative device development both domestically and internationally in the previous 2023. This article aims to review the progress of TAVR in the past year from the perspectives of international, and domestic research development of application. It highlights new clinical and basic research findings both domestically and internationally, the emergence of new devices and technologies, and the development and use of TAVR in China. Finally, it provides an outlook on the trajectory of TAVR development in 2024.

Citation： PAN Wenzhi, FANG Yanxing, LI Jie, LI Fei, ZHOU Daxin, GE Junbo. Transcatheter aortic valve replacement (TAVR) annual report 2023. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(4): 498-503. doi: 10.7507/1007-4848.202401070 Copy

1.	Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med, 2023, 389(21): 1949-1960.
2.	Forrest JK, Deeb GM, Yakubov SJ, et al. 4-year outcomes of patients with aortic stenosis in the Evolut Low Risk Trial. J Am Coll Cardiol, 2023, 82(22): 2163-2165.
3.	Madhavan MV, Kodali SK, Thourani VH, et al. Outcomes of SAPIEN 3 transcatheter aortic valve replacement compared with surgical valve replacement in intermediate-risk patients. J Am Coll Cardiol, 2023, 82(2): 109-123.
4.	O'Hair D, Yakubov SJ, Grubb KJ, et al. Structural valve deterioration after self-expanding transcatheter or surgical aortic valve implantation in patients at intermediate or high risk. JAMA Cardiol, 2023, 8(2): 111-119.
5.	Galper BZ, Chinnakondepalli KM, Wang K, et al. Economic outcomes of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis and low surgical risk: Results from the PARTNER 3 Trial. Circulation, 2023, 147(21): 1594-1605.
6.	Ryffel C, Windecker S, Pilgrim T. Expansion of transcatheter aortic valve implantation and mortality due to aortic stenosis between 2010 and 2019. Circ Cardiovasc Interv, 2023, 16(12): e13104.
7.	Reindl M, Lechner I, Holzknecht M, et al. Cardiac magnetic resonance imaging versus computed tomography to guide transcatheter aortic valve replacement: A randomized, open-label, noninferiority trial. Circulation, 2023, 148(16): 1220-1230.
8.	Okuno T, Tomii D, Lanz J, et al. 5-year outcomes with self-expanding vs. balloon-expandable transcatheter aortic valve replacement in patients with small annuli. JACC Cardiovasc Interv, 2023, 16(4): 429-440.
9.	Rodés-Cabau J, Ribeiro H, Mohammadi S, et al. Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus: A randomized clinical trial. Circulation, 2024, 149(9): 644-655.
10.	Grubb KJ, Shekiladze N, Spencer J, et al. Feasibility of redo-TAVI in self-expanding Evolut valves: A CT analysis from the Evolut Low Risk Trial substudy. EuroIntervention, 2023, 19(4): e330-e339.
11.	Tang G, Spencer J, Rogers T, et al. Feasibility of coronary access following redo-TAVR for Evolut failure: A computed tomography simulation study. Circ Cardiovasc Interv, 2023, 16(11): e13238.
12.	Gallo M, Fovino LN, Blitzer D, et al. Transcatheter aortic valve replacement for structural degeneration of previously implanted transcatheter valves (TAVR-in-TAVR): A systematic review. Eur J Cardiothorac Surg, 2022, 61(5): 967-976.
13.	Kapadia SR, Krishnaswamy A, Whisenant B, et al. Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation. Circulation, 2024, 149(10): 734-743.
14.	Kodali SK, Sorajja P, Meduri CU, et al. Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR. EuroIntervention, 2023, 19(4): E352-E361.
15.	Garcia S, Ye J, Webb J, et al. Transcatheter treatment of native aortic valve regurgitation: The north American experience with a novel device. JACC Cardiovasc Interv, 2023, 16(16): 1953-1960.
16.	Messas E, Ijsselmuiden A, Trifunović-Zamaklar D, et al. Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy: A cohort study. Lancet, 2023, 402(10419): 2317-2325.
17.	Regueiro A, Alperi A, Vilalta V, et al. Safety and efficacy of TAVR with a pressure sensor and pacing guidewire: SAFE-TAVI Trial. JACC Cardiovasc Interv, 2023, 16(24): 3016-3023.
18.	Lin Y, Yang Q, Lin X, et al. Extracellular matrix disorganization caused by ADAMTS16 deficiency leads to bicuspid aortic valve with raphe formation. Circulation, 2024, 149(8): 605-626.
19.	Wang M, Niu G, Chen Y, et al. Development and validation of a deep learning-based fully automated algorithm for pre-TAVR CT assessment of the aortic valvular complex and detection of anatomical risk factors: A retrospective, multicentre study. EBioMedicine, 2023, 96: 104794.
20.	Pan WZ. Novel-transfemoral-aortic-valve-replacement-system-hanchor-valve-pure-native-aortic. TCT conference. San Francisco, USA. 2023, 10-25. URL: https://www.md.com/slide/novel-transfemoral-aortic-valve-replacement-system-hanchor-valve-pure-native-aortic.
21.	Chen S, Lin D, Qi Y, et al. A transcatheter "Sandwich" valve-in-valve implantation for pure aortic regurgitation: A report of 2 cases. Cardiology Plus, 2023, 8(3): 211-215.
22.	中国医师协会心血管内科医师分会结构性心脏病学组. 单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023. 中国介入心脏病学杂志, 2023, 31(11): 801-809.
23.	Ge J, Zhou D, Zhang X, et al. Preliminary implantation of a novel TAVR device with polymeric leaflets for symptomatic calcific aortic disease. JACC Case Rep, 2023, 17: 101901.

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med, 2023, 389(21): 1949-1960.
2. Forrest JK, Deeb GM, Yakubov SJ, et al. 4-year outcomes of patients with aortic stenosis in the Evolut Low Risk Trial. J Am Coll Cardiol, 2023, 82(22): 2163-2165.
3. Madhavan MV, Kodali SK, Thourani VH, et al. Outcomes of SAPIEN 3 transcatheter aortic valve replacement compared with surgical valve replacement in intermediate-risk patients. J Am Coll Cardiol, 2023, 82(2): 109-123.
4. O'Hair D, Yakubov SJ, Grubb KJ, et al. Structural valve deterioration after self-expanding transcatheter or surgical aortic valve implantation in patients at intermediate or high risk. JAMA Cardiol, 2023, 8(2): 111-119.
5. Galper BZ, Chinnakondepalli KM, Wang K, et al. Economic outcomes of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis and low surgical risk: Results from the PARTNER 3 Trial. Circulation, 2023, 147(21): 1594-1605.
6. Ryffel C, Windecker S, Pilgrim T. Expansion of transcatheter aortic valve implantation and mortality due to aortic stenosis between 2010 and 2019. Circ Cardiovasc Interv, 2023, 16(12): e13104.
7. Reindl M, Lechner I, Holzknecht M, et al. Cardiac magnetic resonance imaging versus computed tomography to guide transcatheter aortic valve replacement: A randomized, open-label, noninferiority trial. Circulation, 2023, 148(16): 1220-1230.
8. Okuno T, Tomii D, Lanz J, et al. 5-year outcomes with self-expanding vs. balloon-expandable transcatheter aortic valve replacement in patients with small annuli. JACC Cardiovasc Interv, 2023, 16(4): 429-440.
9. Rodés-Cabau J, Ribeiro H, Mohammadi S, et al. Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus: A randomized clinical trial. Circulation, 2024, 149(9): 644-655.
10. Grubb KJ, Shekiladze N, Spencer J, et al. Feasibility of redo-TAVI in self-expanding Evolut valves: A CT analysis from the Evolut Low Risk Trial substudy. EuroIntervention, 2023, 19(4): e330-e339.
11. Tang G, Spencer J, Rogers T, et al. Feasibility of coronary access following redo-TAVR for Evolut failure: A computed tomography simulation study. Circ Cardiovasc Interv, 2023, 16(11): e13238.
12. Gallo M, Fovino LN, Blitzer D, et al. Transcatheter aortic valve replacement for structural degeneration of previously implanted transcatheter valves (TAVR-in-TAVR): A systematic review. Eur J Cardiothorac Surg, 2022, 61(5): 967-976.
13. Kapadia SR, Krishnaswamy A, Whisenant B, et al. Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation. Circulation, 2024, 149(10): 734-743.
14. Kodali SK, Sorajja P, Meduri CU, et al. Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR. EuroIntervention, 2023, 19(4): E352-E361.
15. Garcia S, Ye J, Webb J, et al. Transcatheter treatment of native aortic valve regurgitation: The north American experience with a novel device. JACC Cardiovasc Interv, 2023, 16(16): 1953-1960.
16. Messas E, Ijsselmuiden A, Trifunović-Zamaklar D, et al. Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy: A cohort study. Lancet, 2023, 402(10419): 2317-2325.
17. Regueiro A, Alperi A, Vilalta V, et al. Safety and efficacy of TAVR with a pressure sensor and pacing guidewire: SAFE-TAVI Trial. JACC Cardiovasc Interv, 2023, 16(24): 3016-3023.
18. Lin Y, Yang Q, Lin X, et al. Extracellular matrix disorganization caused by ADAMTS16 deficiency leads to bicuspid aortic valve with raphe formation. Circulation, 2024, 149(8): 605-626.
19. Wang M, Niu G, Chen Y, et al. Development and validation of a deep learning-based fully automated algorithm for pre-TAVR CT assessment of the aortic valvular complex and detection of anatomical risk factors: A retrospective, multicentre study. EBioMedicine, 2023, 96: 104794.
20. Pan WZ. Novel-transfemoral-aortic-valve-replacement-system-hanchor-valve-pure-native-aortic. TCT conference. San Francisco, USA. 2023, 10-25. URL: https://www.md.com/slide/novel-transfemoral-aortic-valve-replacement-system-hanchor-valve-pure-native-aortic.
21. Chen S, Lin D, Qi Y, et al. A transcatheter "Sandwich" valve-in-valve implantation for pure aortic regurgitation: A report of 2 cases. Cardiology Plus, 2023, 8(3): 211-215.
22. 中国医师协会心血管内科医师分会结构性心脏病学组. 单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023. 中国介入心脏病学杂志, 2023, 31(11): 801-809.
23. Ge J, Zhou D, Zhang X, et al. Preliminary implantation of a novel TAVR device with polymeric leaflets for symptomatic calcific aortic disease. JACC Case Rep, 2023, 17: 101901.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Transcatheter aortic valve replacement (TAVR) annual report 2023

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content